Rational design and development of HDAC inhibitors for breast cancer treatment - Université de Lille Accéder directement au contenu
Article Dans Une Revue Current Pharmaceutical Design Année : 2021

Rational design and development of HDAC inhibitors for breast cancer treatment

Résumé

Background: Breast cancer is the most prevalent cancer amongst females across the globe and with over 2 million new cases reported in 2018, it poses huge economic burden to the already dwindling public health. A dearth of therapies in the pipeline to treat triple-negative breast cancers, and acquisition of resistance against existing line of treatments urges the need to strategize novel therapeutics in order to add new drugs to the pipeline. HDAC inhibitors (HDACi) is one such class of small molecule inhibitors that target histone deacetylases to bring about chromosomal remodelling and normalize dysregulated gene expression that marks breast cancer progression. Objective: While four HDACi have been approved by the FDA for treatment of different cancer types, no HDACi is specifically earmarked for clinical management of breast cancer. Owing to the differential HDAC expression pertaining to different types of breast cancers, isoform-selective HDAC inhibitors need to be discovered. Conclusion: This review attempts to set the stage for rational structure-based discovery of isoform-selective HDACi by providing structural insights into different HDACs and their catalytic folds based on their classes and individual landscape. Development of inhibitors in accordance with the differential expression of HDAC isoforms exhibited in breast cancer cells is a promising strategy to rationally design selective and effective inhibitors, adopting a ‘personalized-medicine’ approach.
Fichier principal
Vignette du fichier
P21.28 Revised manuscript_BMS-CPD-2021-HT164-2670-13_27Aug copy.pdf (1.41 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03381999 , version 1 (18-10-2021)
hal-03381999 , version 2 (21-10-2022)

Identifiants

Citer

Deepansh Mody, Julie Bouckaert, Savvas N. Savvides, Vibha Gupta. Rational design and development of HDAC inhibitors for breast cancer treatment. Current Pharmaceutical Design, 2021, Current Pharmaceutical Design, ⟨10.2174/1381612827666210917143953⟩. ⟨hal-03381999v2⟩

Collections

CNRS UNIV-LILLE
32 Consultations
133 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More